TrialEuropean urology2022

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.

Shankar Siva et al.PubMed ↗Publisher ↗

No numbers read from the abstract.